Sanofi Healthcare Gets CDSCO Panel Nod To Study Amlitelimab for atopic dermatitis Dr. Divya Colin2 Feb 2025 5:00 PM ISTNew Delhi: Drug major Sanofi Healthcare India has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard...
Sanofi gets CDSCO Panel nod to study Amlitelimab Dr. Divya Colin31 Oct 2024 5:30 PM ISTNew Delhi: The drug major Sanofi has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Submit clinical study data conducted in adults: CDSCO Panel Tells Sanofi on atopic dermatitis drug Dr. Divya Colin4 Aug 2024 6:00 PM ISTNew Delhi: Responding to the protocol amendment proposal for Amlitelimab study, the Subject Expert Committee (SEC) functional under the Central Drug...
Submit preliminary analysis of primary data of subjects above 18 years in India: CDSCO Panel Tells Sanofi on Amlitelimab study Dr. Divya Colin19 May 2024 6:00 PM ISTNew Delhi: After considering the phase III clinical study protocol of the monoclonal antibody Amlitelimab in the treatment of moderate-to-severe...
Amlitelimab Phase 2b data show potential best-in-class profile in atopic dermatitis: Sanofi Ruchika Sharma16 Oct 2023 1:30 PM ISTParis: Sanofi has announced positive results from a Phase 2b study (STREAM-AD). The results showed that amlitelimab significantly improved signs...
Amlitelimab shows promising results for Atopic Dermatitis Jacinthlyn Sylvia15 Oct 2023 8:00 PM ISTSanofi unveiled promising outcomes from its Phase 2b trial, STREAM-AD, during the European Academy of Dermatology and Venereology (EADV) 2023...
Sanofi gets CDSCO panel nod to study atopic dermatitis drug Amlitelimab Dr. Divya Colin27 Sept 2023 6:00 PM ISTNew Delhi: The drug major Sanofi has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
